Expert Interview
Looking at the approval of Edwards' transcatheter aortic valve replacement (TAVR) therapy for Patients With Asymptomatic Severe Aortic Stenosis
Ticker(s): EW, MDT, ABTInstitution: UCLA Medical Center
- Interventional cardiologist at UCLA , Medical Director of the Structural Heart Disease Program & Associate Clinical Professor of Medicine at the David Geffen School of Medicine.
- Manages 25 patients with ATTR-CM.
- Areas of expertise include coronary artery disease and structural and valvular heart disease while specializing in complex percutaneous coronary interventions including the use of rotational atherectomy.
Describe your background and practice setting
Added By: ben_adminHow many TAVR procedures do you conduct yearly?
Added By: ben_adminWhich TAVR platforms do you currently utilize in your setting?
Added By: ben_adminWhat are your thoughts on the FDA approval of the EARLY-TAVR trial?
Added By: ben_adminWhat are the key differences between valve systems like SAPIEN and CoreValve, and how do these affect patient outcomes and procedural choices?
Added By: ben_adminHow durable are TAVR valves compared to surgical ones, and what follow-up protocol do you recommend for asymptomatic patients?
Added By: ben_adminWhat are your thoughts on the EARLY-TAVR trial's findings for asymptomatic patients, and how might it impact timing and decision-making for interventions?
Added By: ben_adminDo you foresee changes in procedural volumes or valve preferences based on this trial, and how might newer technologies like Abbott's or Boston Scientific's valves impact the market?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
